Open science in clinical trials and debates about the role of research ethics committees: insights from the European Union
Open science is expected to become an integral component of clinical trials, but, in practice, it is fragmented across various guidelines, laws, funder rules, registry requirements and publishing standards. This fragmentation creates practical challenges for research ethics committees (RECs), which are responsible for protecting participants and reviewing transparency commitments often managed and enforced by other actors such as sponsors, regulators, journals and data access bodies. Focusing on the EU governance context, this multidisciplinary normative analysis examines four transparency practices – open publications, trial registration, results reporting and data sharing – and traces how each has evolved from softer ethical expectations into more institutionalized governance structures. It then analyses what these developments mean for REC review in practice. The paper argues that the mentioned developments do not impact REC work evenly: in some areas, they clarify points of REC involvement, while in others, they mainly reveal the limits of REC influence and the need for clearer responsibility boundaries.
Authors
- Vygintas Aliukonis (ORCID: https://orcid.org/0000-0002-2636-6161)
- Margarita Poškutė (ORCID: https://orcid.org/0000-0002-8291-189X)
- Eugenijus Gefenas (ORCID: https://orcid.org/0000-0001-5004-3322)
- Vilma Lukaševičienė (ORCID: https://orcid.org/0000-0001-8277-7603)
Institutions
- Vilnius University (LT)
Publication Details
- Journal
- Health Research Policy and Systems
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1186/s12961-026-01556-4
- Primary Topic
- Ethics in Clinical Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00